Atsuko Sakurai-Sangria
Director, CMC Centivax
Atsuko is the Director of CMC at Centivax, a universal immunity company developing broad-spectrum vaccines and antibodies using a proprietary computational immune-engineering platform. She leads CMC activities, establishes process and analytical control strategies to advance Centivax’s highly innovative vaccines and therapeutics from development through clinical manufacturing.
Seminars
Wednesday 30th September 2026
Leveraging NGS to Enable Scalable QC & Process Control for Complex Multivariant mRNA Vaccines
9:00 am
- Exploring how NGS can consolidate multiple critical quality attributes into a single, data-rich analytical workflow for complex mRNA products
- Overcoming the QC and CMC challenges associated with 22-component multivariant RNA vaccines where traditional analytical methods struggle to assess integrity, identity & potency at scale
- Sharing lessons learned from implementing next-generation sequencing approaches for in-process control, release testing & regulatory readiness in next-generation mRNA vaccine development
